RU2271829C2 - Способ повышения эффективности противоопухолевых агентов - Google Patents

Способ повышения эффективности противоопухолевых агентов Download PDF

Info

Publication number
RU2271829C2
RU2271829C2 RU2001131894/14A RU2001131894A RU2271829C2 RU 2271829 C2 RU2271829 C2 RU 2271829C2 RU 2001131894/14 A RU2001131894/14 A RU 2001131894/14A RU 2001131894 A RU2001131894 A RU 2001131894A RU 2271829 C2 RU2271829 C2 RU 2271829C2
Authority
RU
Russia
Prior art keywords
cisplatin
epo
mice
erythropoietin
platinum
Prior art date
Application number
RU2001131894/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2001131894A (ru
Inventor
М. Стивен ПАЙВЕР (US)
М. Стивен ПАЙВЕР
Дэвид Ф. СИЛВЕР (US)
Дэвид Ф. СИЛВЕР
Original Assignee
Хелт Рисерч, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хелт Рисерч, Инк. filed Critical Хелт Рисерч, Инк.
Publication of RU2001131894A publication Critical patent/RU2001131894A/ru
Application granted granted Critical
Publication of RU2271829C2 publication Critical patent/RU2271829C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
RU2001131894/14A 1999-04-27 2000-04-24 Способ повышения эффективности противоопухолевых агентов RU2271829C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/300,124 US6171620B1 (en) 1999-04-27 1999-04-27 Method of enhancing the efficacy of anti-tumor agents
US09/300,124 1999-04-27

Publications (2)

Publication Number Publication Date
RU2001131894A RU2001131894A (ru) 2003-08-27
RU2271829C2 true RU2271829C2 (ru) 2006-03-20

Family

ID=23157813

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001131894/14A RU2271829C2 (ru) 1999-04-27 2000-04-24 Способ повышения эффективности противоопухолевых агентов

Country Status (18)

Country Link
US (3) US6171620B1 (cg-RX-API-DMAC7.html)
EP (1) EP1212068A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002542296A (cg-RX-API-DMAC7.html)
KR (1) KR100693796B1 (cg-RX-API-DMAC7.html)
CN (1) CN1188137C (cg-RX-API-DMAC7.html)
AU (1) AU781301B2 (cg-RX-API-DMAC7.html)
BG (1) BG64940B1 (cg-RX-API-DMAC7.html)
BR (1) BR0010082A (cg-RX-API-DMAC7.html)
CA (1) CA2368618C (cg-RX-API-DMAC7.html)
HU (1) HUP0200840A3 (cg-RX-API-DMAC7.html)
IL (1) IL146012A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA01010899A (cg-RX-API-DMAC7.html)
NO (1) NO20015227L (cg-RX-API-DMAC7.html)
NZ (1) NZ514521A (cg-RX-API-DMAC7.html)
PL (1) PL350918A1 (cg-RX-API-DMAC7.html)
RU (1) RU2271829C2 (cg-RX-API-DMAC7.html)
WO (1) WO2000064455A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200108012B (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
JP2003531179A (ja) 2000-04-26 2003-10-21 クイーンズ ユニバーシティ アット キングストン 悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
PL2368554T3 (pl) 2003-04-08 2015-05-29 Progenics Pharm Inc Preparaty farmaceutyczne zawierające metylonaltrekson
DE10361813A1 (de) * 2003-12-30 2005-09-08 Bionethos Holding Gmbh Verfahren zur Regeneration von Gewebe
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
WO2008121348A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
EP2310038A4 (en) * 2008-05-15 2012-03-14 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCE OF IMPROVENCE WITH COMPOUNDS WITH ERYTHROPOETIN EFFECT
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
PL230756B1 (pl) * 2015-09-11 2018-12-31 Univ Medyczny W Bialymstoku Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
JPWO2019083023A1 (ja) * 2017-10-26 2020-11-12 国立大学法人 筑波大学 癌の治療に使用するための組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2111750C1 (ru) * 1995-02-23 1998-05-27 Институт элементоорганических соединений РАН Модификатор для противоопухолевой терапии

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
JPH1067678A (ja) * 1996-06-20 1998-03-10 Chugai Pharmaceut Co Ltd 肝疾患治療用医薬組成物
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2111750C1 (ru) * 1995-02-23 1998-05-27 Институт элементоорганических соединений РАН Модификатор для противоопухолевой терапии

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMES R.D. ET AL. Recombinant human erythropoietin in patients with ovarian carcinoma and anaemia secondary to cisplatin and carboplatin chemotherapy: preliminary results // Acta Haematol. 1992; 87 Suppi 1:12-5, abstr. PubMed. CASE D.C. Jr ET AL. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy // J Nati Cancer Inst. 1993 May 19; 85(10):801-6, abstr. PubMed. Большая медицинская энциклопедия, гл. ред. акад. Б.В.Петровский, М., Советская энциклопедия, 1974, том 1, с.516 столб.1546-1547. MASUNAGA S. ET AL. Enchancement of chemosensitivity of quiescent cell populations in murine solid tumors using nicotinamide // Chemotherapy. 1994; 40(6): 418-26, abstr. PubMed. РЛС России, Энциклопедия лекарств, 1999, подп. в печ. 15.08.1998, с.738, 1011. *

Also Published As

Publication number Publication date
CA2368618A1 (en) 2000-11-02
AU4486300A (en) 2000-11-10
KR100693796B1 (ko) 2007-03-12
NO20015227L (no) 2001-12-27
HUP0200840A3 (en) 2003-04-28
EP1212068A4 (en) 2007-03-14
WO2000064455A1 (en) 2000-11-02
MXPA01010899A (es) 2003-06-24
KR20020000557A (ko) 2002-01-05
CN1352561A (zh) 2002-06-05
US6620779B2 (en) 2003-09-16
HUP0200840A2 (hu) 2002-07-29
CN1188137C (zh) 2005-02-09
NO20015227D0 (no) 2001-10-25
ZA200108012B (en) 2003-03-26
JP2002542296A (ja) 2002-12-10
BG64940B1 (bg) 2006-10-31
CA2368618C (en) 2011-03-01
NZ514521A (en) 2003-07-25
US6171620B1 (en) 2001-01-09
AU781301B2 (en) 2005-05-12
BR0010082A (pt) 2002-01-15
US20010000730A1 (en) 2001-05-03
US6426094B2 (en) 2002-07-30
IL146012A0 (en) 2002-07-25
US20020198153A1 (en) 2002-12-26
EP1212068A1 (en) 2002-06-12
PL350918A1 (en) 2003-02-10
BG106057A (en) 2002-04-30

Similar Documents

Publication Publication Date Title
US6426094B2 (en) Method of enhancing the efficacy of anti-tumor agents
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
TWI522105B (zh) 偏亞砷酸鈉於治療癌疼痛及炎症之用途
US20120128667A1 (en) Pentamidine combinations for treating cancer
HU230273B1 (hu) Egy epotilon analóg és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére
WO2020226526A1 (en) Method for increasing cancer patient's haemoglobin level
NISHIHIRA et al. Postoperative cancer therapy for patients with carcinoma of the thoracic esophagus: an attempt of aggressive chemotherapy combined with proper nutritional support for patients with distant node metastasis
Gonzalez et al. Continuous intravenous infusion combination chemotherapy for head and neck squamous cell carcinoma
RU2773153C1 (ru) Способ повышения уровня гемоглобина в крови у пациента, больного раком
Miller et al. Phase II trial of bisantrene in non-small cell lung cancer
KR20140033522A (ko) 비뇨 생식기암 및 이의 전이 치료용 비소산, 이것의 나트륨염 및 이것의 유도체를 함유하는 약학 조성물

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110425